119
Participants
Start Date
December 10, 2012
Primary Completion Date
August 28, 2018
Study Completion Date
August 28, 2018
Derazantinib low dose range
Derazantinib was administered orally at dose levels from 25 mg QOD - 200 mg QD on a 28-day schedule.
Derazantinib middle dose range
Derazantinib was administered orally at dose levels from 250 mg QD - 325 mg QD on a 28-day schedule.
Derazantinib high dose range
Derazantinib was administered orally at dose levels from 400 mg QD - 425 mg QD on a 28-day schedule.
Derazantinib at recommended phase 2 dose (RP2D)
Derazantinib was administered orally at the recommended phase 2 dose of 300 mg QD on a 28-day schedule.
Montefiore-Einstein Center for Cancer Care, The Bronx
University of Pennsylvania Hospital, Philadelphia
Istituto Clinico Humanitas, Milan
Istituto Nazionale Tumori (National Cancer Institute), Milan
Emory University, Winship Cancer Institute, Atlanta
Instituto Oncologico Veneto, IRCCS, Padua
Karmanos Cancer Institute, Detroit, Detroit
Azienda Ospedaliero-Universitaria Pisana - U.O. Oncologia Medica 2 Univ., Pisa
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio
Scottsdale Healthcare Research Institute, Scottsdale
Comprehensive Cancer Centers of Nevada, Las Vegas
University of Washington, Seattle
Lead Sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
INDUSTRY
Basilea Pharmaceutica
INDUSTRY